HCG Q2 FY27 Unaudited Results: Standalone Loss of ₹204 Lakhs, Consolidated Profit of ₹925 Lakhs
Healthcare Global Enterprises Limited reported unaudited results for the quarter ended September 30, 2026. Standalone profit was a loss of ₹204 lakhs, down from ₹558 lakhs year-on-year. Consolidated profit was ₹925 lakhs, down from ₹2,066 lakhs year-on-year. Standalone revenue from operations was ₹39,604 lakhs and consolidated revenue was ₹73,016 lakhs.
Financial results, especially a decline in profitability and a shift to a standalone loss, are material events that significantly impact investor sentiment and the company's valuation.
The company reported a standalone loss for the quarter and a decrease in both standalone and consolidated profits compared to the previous year, indicating a negative financial performance trend.
Healthcare Global Enterprises Limited (HCG) announced its unaudited financial results for the quarter and six months ended September 30, 2026. The Board of Directors, in their meeting held on November 5, 2026, approved these results.
On a standalone basis, HCG reported a loss of ₹204 lakhs for the quarter ended September 30, 2026, compared to a profit of ₹558 lakhs in the corresponding quarter of the previous year. For the six months ended September 30, 2026, the standalone profit stood at ₹354 lakhs, a decrease from ₹1,423 lakhs in the same period last year. The revenue from operations for the standalone entity was ₹39,604 lakhs for the quarter and ₹77,129 lakhs for the six months.
On a consolidated basis, HCG reported a profit of ₹925 lakhs for the quarter ended September 30, 2026, a decrease from ₹2,066 lakhs in the corresponding quarter of the previous year. For the six months ended September 30, 2026, the consolidated profit was ₹2,571 lakhs, compared to ₹2,664 lakhs in the same period last year. The consolidated revenue from operations was ₹73,016 lakhs for the quarter and ₹142,355 lakhs for the six months.
The company also reported exceptional items. For standalone results, an exceptional item of ₹(661) lakhs was recognized towards estimated customs duty liability. For consolidated results, an exceptional item of ₹(1,159) lakhs was recognized, which includes the customs duty liability and a gain on disposal of a subsidiary (refer note 2(ii)).
The meeting of the Board of Directors commenced at 11:15 a.m. and concluded at 07:45 p.m. on November 5, 2026.
What to do with a filing like this
Healthcare Global Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Healthcare Global Enterprises Limited. Read the original for the full detail.